The pharmaceutical industry, as well as its top management, is now going through a tough time. Customer behaviour is changing, as well as a predatory merger and acquisition cycle is developing with the introduction of fresh new ideas. Well, this followed increased therapeutic rivalry and cost reduction, which were driven by payer consolidation, prompting the majority of companies to revaluate their business and marketing strategies, according to a recent study on the subject.